NorthWest Biotherapeutics Inc (NWBO)

[alexander77]

Thank you all for your answers. All I know from oncologists is that there is some enthousiasm about the potential of dendritic vaccines. What I think is that Merck will buy them out for cheap for something between 5 and 20 billion when P3 results are good, considering the rest of the pipeline (DCVax direct).
The odds of approval is now in the hands of the regulatory agencies allowing NWBO an adaptation of the SAP. I like the quietness from management abou that. It must be nerve wrecking for shorts because: news could come in any day now. And this news will enhance the odds of FDA and EMEA approval + will trigger a short squeeze.